Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
Issued Date
2022-05-01
Resource Type
eISSN
20770383
Scopus ID
2-s2.0-85129915955
Journal Title
Journal of Clinical Medicine
Volume
11
Issue
10
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Medicine Vol.11 No.10 (2022)
Suggested Citation
Kaewput C., Vinjamuri S. Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends. Journal of Clinical Medicine Vol.11 No.10 (2022). doi:10.3390/jcm11102738 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85912
Title
Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
There is now an increasing trend for targeting cancers to go beyond early diagnosis and actually improve Progression-Free Survival and Overall Survival. Identifying patients who might benefit from a particular targeted treatment is the main focus for Precision Medicine. Radiolabeled ligands can be used as predictive biomarkers which can confirm target expression by cancers using positron emission tomography (PET). The same ligand can subsequently be labeled with a therapeutic radionuclide for targeted radionuclide therapy. This combined approach is termed “Theranostics”. The prostate-specific membrane antigen (PSMA) has emerged as an attractive diagnostic and therapeutic target for small molecule ligands in prostate cancer. It can be labeled with either positron emitters for PET-based imaging or beta and alpha emitters for targeted radionuclide therapy. This review article summarizes the important concepts for Precision Medicine contributing to improved diagnosis and targeted therapy of patients with prostate cancer and we identify some key learning points and areas for further research.